Disappointing results with Tc-99m tetrofosmin for detecting medullary thyroid carcinoma metastases comparison with Tc-99m VDMSA and Tl-201

Clinical Nuclear Medicine

Volumn 24, Issue 9, 1999, Pages 678-683

  Adalet, Iŝik ^a,b   Demirkale, Pelin ^a   Ünal, Seher ^a   Oůz, Harika ^a   Alagöl, Faruk ^a   Cantez, Sema ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Emlak Konut Sitesi   (Turkey)

Author keywords

Medullary Thyroid Carcinoma; Tc 99m Tetrofosmin; Tc 99m VDMSA; Tl 201

Indexed keywords

CALCITONIN; SUCCIMER TC 99M; TETROFOSMIN TC 99M; THALLIUM 201;

ADULT; AGED; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER LOCALIZATION; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; THYROID MEDULLARY CARCINOMA; WHOLE BODY SCINTISCANNING;

ADULT; AGED; CALCITONIN; CARCINOMA, MEDULLARY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M DIMERCAPTOSUCCINIC ACID; THALLIUM RADIOISOTOPES; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 0032818584     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-199909000-00008     Document Type: Article

References (23)

1. Williams ED: Medullary carcinoma of the thyroid. In: De Groot LJ, ed. Endocrinology. Philadelphia: WB Saunders, 1989, pp 1132-50.
2. Kallinowski F, Buhr HJ, Meybier H, Eberhardt M, Herferth C: Medullary carcinoma of the thyroid-therapeutic strategy derived from 15 years of experience. Surgery 114:491, 1993.
3. Clarke SEM: Medullary thyroid cancer. In: Murray IPC, Elle PC, Strauss HW, eds. Nuclear Medicine in Clinical Diagnosis and Treatment. New York: Churchill Livingstone, 1994, pp 677-85.
4. Clarke SEM, Lazarus CR, Wraight P, Sampson C, Maisey MN: Pentavalent Tl-201 DMSA, 1-131 MIBG and Tl-201 MDP - An evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid. J Nucl Med 29:33, 1988.
5. Lebouthillier G, Morais J, Picard M, et al: Tl-201 sestamibi and other agents in the detection of metastatic medullary carcinoma of the thyroid. Clin Nucl Med 18:657, 1993.
6. Jones S, Hendel RC: Technetium-99m tetrofosmin: A new myocardial perfusion agent. J Nucl Med Technol 21:191, 1993.
7. Koĉak M, Adalet I, Ece T, et al: Detection of primary lung cancer and its metastases with Tl-201 Tetrofosmin: Preliminary results [Abstract]. Eur J Nucl Med 22:844, 1995.
8. Atasever T, Gökĉora N, Vural G: Evaluation of malignant and benign lung lesions with Tl-201 Tetrofosmin. Nucl Med Commun 17:577, 1996.
9. Adalet I, Demirkol O, Müslümanoǧlu M, Bozfakioǧlu Y, Cantez S: Tc-99m Tetrofosmin scintigraphy in the evaluation of palpable breast masses. Nucl Med Commun 18:118, 1997.
10. Ünal S, Menda Y, Adalet I, et al: The role of thallium-201, Tl-201 tetrofosmin and 1-131 in detection of differentiated thyroid carcinoma metastases. J Nucl Med 39:1897, 1998.
11. Blower PJ, Singh J, Clarke SEM: The chemical identity of pentavalent technetium 99m-dimercaptosuccinic acid. J Nucl Med 32:845, 1991.
12. Montravers F, Coutris G, Sarda L, Mensch B, Talbot JN: Utility of thallium-201 and iodine-123 metaiodobenzylguanidine in the scintigraphic detection of neuroendocrine neoplasia. Eur J Nucl Med 20:1070, 1993.
13. Uǧur Ö, Kostakoǧlu L, Güler N, et al: Comparison of Tc-99m V DMSA, Tl-201 and Tc-99m MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid. Eur J Nucl Med 23:1367, 1996.
14. O'Driscoll CM, Baker F, Casey MJ, Duffy GJ: Localization of recurrent medullary thyroid carcinoma with technetium-99m methoxyisobutylnitrile scintigraphy: A case report. J Nucl Med 32:2281, 1991.
15. Learoyd DL, Roach PJ, Briggs GM, et al: Technetium-99m sestamibi scanning in recurrent medullary thyroid carcinoma. J Nucl Med 38:227, 1997.
16. Behr TM, Gratz S, Markus PM, et al: Enhanced bilateral somatostatin receptor expression in mediastinal lymph nodes (chimney sign) in occult metastatic medullary thyroid cancer: A typical site of tumour manifestation? Eur J Nucl Med 24:184, 1997.
17. Silberstein EB: The treatment of thyroid malignancies. In: Henkin RE, Boles MA, Dillehay CL, et al., eds. Nuclear Medicine. St. Louis: CV Mosby, 1996, pp 1557-67.
18. Adalet I, Demirkale P, Oǧuz H, et al: Detection of medullary thyroid carcinoma metastases by Tc-99m tetrofosmin: Comparison with Tc-99m V DMSA and Tl-201 [Abstract]. Eur J Nucl Med 23:1059, 1996.
19. Baudin E, Lumbroso J, Schlumberger M, et al: Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 37:912, 1996.
20. Ohta H, Endo K, Fujita T, et al: Imaging of head and neck tumors with technetium (V)-99m DMSA. A new tumor seeking agent. Clin Nucl Med 10:855, 1985.
21. Waxman AD: Thallium-201 in nuclear oncology. In: Freeman LM, ed. Nuclear Medicine Annual. New York: Raven Press, 1991, pp 193-209.
22. Higley B, Smith FW, Smith T, et al: Technetium-99m-1,2-bis[(bis(2 ethoxyethyl) phosphino] ethane: Human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 34:30, 1993.
23. Arbab AS, Koizumi K, Toyama K, Araki T: Uptake of technetium-99m tetrofosmin, technetium-99m-MIBI and thallium-201 in tumor cell lines. J Nucl Med 37:1551, 1996.